MarketBeat
14 Nov 2026, 09:12 UTC · 2d ago
Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”
Impact · against what's priced in
Natera provides concrete milestones for its growth trajectory, specifically a 2026 revenue floor of $3B and a clear path toward its 2029 target via ASP increases. The completion of the FIND-CRC study enrollment introduces a significant binary catalyst for 2027 that expands the addressable market beyond current monitoring expectations.
- NTRA+0.50
No priced-in read yet
- In context
The guidance of >$3B revenue for 2026 and >$1B for Signatera this year provides a concrete medium-term bridge to the 2029 target. Additionally, the move to a $1,450 ASP for Signatera and the upcoming 2027 FIND-CRC data create tangible catalysts for margin expansion and market broadening.

- healthcare
- NTRA
- cancer testing
- ceo transition
- genetic testing
- medicare reimbursement
- molecular diagnostics
- oncology
- revenue guidance
Search tags




